DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $112.25.

Several research firms have recently issued reports on DXCM. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group restated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Oppenheimer lowered their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Royal Bank of Canada reduced their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Finally, UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th.

DexCom Trading Down 0.4 %

Shares of DexCom stock opened at $67.29 on Monday. The company has a market capitalization of $26.76 billion, a P/E ratio of 43.41, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The stock has a fifty day simple moving average of $73.66 and a 200 day simple moving average of $107.23. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, sell-side analysts anticipate that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,824 shares of company stock valued at $126,390. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. Crewe Advisors LLC purchased a new stake in DexCom in the first quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom in the 2nd quarter valued at $25,000. Riverview Trust Co bought a new position in shares of DexCom during the 1st quarter valued at $32,000. Sachetta LLC raised its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Finally, Sound Income Strategies LLC raised its position in DexCom by 41.7% in the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock worth $47,000 after purchasing an additional 100 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.